Lexicon Pharmaceuticals, Inc. $LXRX Shares Bought by Siren L.L.C.

Siren L.L.C. lifted its holdings in shares of Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) by 13.8% in the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 44,303,518 shares of the biopharmaceutical company’s stock after buying an additional 5,384,615 shares during the period. Lexicon Pharmaceuticals comprises 1.9% of Siren L.L.C.’s investment portfolio, making the stock its 14th biggest holding. Siren L.L.C. owned approximately 0.10% of Lexicon Pharmaceuticals worth $69,113,000 as of its most recent SEC filing.

Several other hedge funds have also modified their holdings of the business. Bank of Nova Scotia purchased a new stake in shares of Lexicon Pharmaceuticals in the first quarter valued at approximately $115,000. Bank of New York Mellon Corp raised its position in Lexicon Pharmaceuticals by 43.6% in the first quarter. Bank of New York Mellon Corp now owns 27,459 shares of the biopharmaceutical company’s stock worth $43,000 after acquiring an additional 8,335 shares in the last quarter. R Squared Ltd raised its position in Lexicon Pharmaceuticals by 45.0% in the first quarter. R Squared Ltd now owns 67,526 shares of the biopharmaceutical company’s stock worth $105,000 after acquiring an additional 20,947 shares in the last quarter. Virtu Financial LLC acquired a new stake in Lexicon Pharmaceuticals in the fourth quarter valued at $42,000. Finally, Invesco Ltd. lifted its holdings in Lexicon Pharmaceuticals by 14.1% in the fourth quarter. Invesco Ltd. now owns 594,883 shares of the biopharmaceutical company’s stock valued at $684,000 after acquiring an additional 73,480 shares during the period. 74.70% of the stock is owned by institutional investors and hedge funds.

Lexicon Pharmaceuticals Stock Up 2.2%

LXRX opened at $2.30 on Friday. The company has a debt-to-equity ratio of 0.24, a quick ratio of 18.77 and a current ratio of 18.80. The company has a market cap of $1.02 billion, a price-to-earnings ratio of -32.85 and a beta of 1.05. Lexicon Pharmaceuticals, Inc. has a one year low of $1.00 and a one year high of $2.68. The business’s fifty day moving average is $2.16 and its two-hundred day moving average is $1.78.

Lexicon Pharmaceuticals (NASDAQ:LXRX) last announced its quarterly earnings results on Thursday, May 7th. The biopharmaceutical company reported ($0.00) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.04) by $0.04. The business had revenue of $21.10 million during the quarter, compared to analysts’ expectations of $9.79 million. Lexicon Pharmaceuticals had a negative return on equity of 18.64% and a negative net margin of 37.46%. Analysts anticipate that Lexicon Pharmaceuticals, Inc. will post -0.17 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of equities analysts have recently issued reports on LXRX shares. Citigroup increased their price target on shares of Lexicon Pharmaceuticals from $2.30 to $3.10 and gave the company a “buy” rating in a report on Monday, May 11th. Weiss Ratings lowered shares of Lexicon Pharmaceuticals from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Wednesday, July 8th. Finally, Zacks Research raised shares of Lexicon Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a report on Friday, July 3rd. One equities research analyst has rated the stock with a Strong Buy rating, two have assigned a Buy rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $4.55.

Lexicon Pharmaceuticals Company Profile

Lexicon Pharmaceuticals, Inc is a biopharmaceutical company focused on the discovery and development of novel medicines through its proprietary genome biology platform. By leveraging large-scale gene knockout libraries, the company identifies potential therapeutic targets and advances them through preclinical and clinical development. Lexicon’s approach emphasizes the translation of genetic insights into targeted therapies for a range of human diseases.

The company’s most advanced product is telotristat ethyl (sold under the brand name XERMELO), an oral treatment approved for the management of carcinoid syndrome diarrhea in patients inadequately controlled by somatostatin analog therapy.